TLX — Telix Pharmaceuticals Limited
$9.15-4.09%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for TLX in the TickerWise workspace.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: AU
- Exchange: NASDAQ
- Employees: 1,120
- Website: https://telixpharma.com
Latest SEC filings for TLX
Latest TLX news
- Telix Pharmaceuticals reports Q3 results Read article
- Telix Reports Third Quarter 2026 Financial Performance Read article
- Ekalia franchit une étape importante dans le déploiement de l’astate-211 aux États-Unis grâce à un accord de collaboration avec Telix Read article
- Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix Read article
- Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S. Read article
- First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18) Read article
- Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.